Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon
- PMID: 338408
- DOI: 10.1007/BF01236316
Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon
Abstract
In 83 insulin-treated diabetics the influence of the duration of insulin treatment on the prevalence of residual insulin secretion was examined by determining the plasma C-peptide concentration before and after intravenous injection of 1 mg of glucagon. In 64 patients, plasma C-etide concentration was also determined before and after a standard meal. There was a good correlation between the C-peptide response to glucagon and to the meal (r = 0.67; p less than 0.0001) suggesting that the glucagon test will predict the B-cell response during everyday life. The predictive value of a positive glucagon test was 84% and of a negative test 100%. A preserved, but reduced, B-cell function was demonstrable in 36 of 83 patients. Residual B-cell function was most frequent in the patients with the shortest duration of diabetes. The metabolic importance of endogenous insulin was demonstrated by the significantly lower insulin requirement in the patients with residual B-cell function.
Similar articles
-
Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.Diabetologia. 1981 Oct;21(4):376-82. doi: 10.1007/BF00252685. Diabetologia. 1981. PMID: 7026333
-
C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.Diabetes. 1977 Jul;26(7):605-10. doi: 10.2337/diab.26.7.605. Diabetes. 1977. PMID: 326604
-
Diurnal profiles of intermediary metabolites in insulin-dependent diabetes and their relationship to different degrees of residual B-cell function.Acta Diabetol Lat. 1981 Apr-Jun;18(2):115-21. doi: 10.1007/BF02098996. Acta Diabetol Lat. 1981. PMID: 7018146
-
C-peptide measurement and its clinical usefulness: a review.Ann Clin Biochem. 1981 Jul;18(Pt 4):200-6. doi: 10.1177/000456328101800402. Ann Clin Biochem. 1981. PMID: 7025733 Review. No abstract available.
-
Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.Diabetes Metab. 1996 Dec;22(6):397-406. Diabetes Metab. 1996. PMID: 8985647 Review.
Cited by
-
Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.J Clin Invest. 1986 Jan;77(1):98-105. doi: 10.1172/JCI112308. J Clin Invest. 1986. PMID: 3511094 Free PMC article.
-
Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.Diabetologia. 1981 Oct;21(4):376-82. doi: 10.1007/BF00252685. Diabetologia. 1981. PMID: 7026333
-
Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.J Endocrinol Invest. 2018 Oct;41(10):1137-1147. doi: 10.1007/s40618-018-0839-7. Epub 2018 Feb 2. J Endocrinol Invest. 2018. PMID: 29396758 Clinical Trial.
-
Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.J Diabetes Investig. 2019 Nov;10(6):1480-1489. doi: 10.1111/jdi.13052. Epub 2019 Apr 19. J Diabetes Investig. 2019. PMID: 30919585 Free PMC article.
-
Plasma C-peptide response to arginine in insulin-dependent diabetic subjects.J Endocrinol Invest. 1980 Jan-Mar;3(1):19-23. doi: 10.1007/BF03348212. J Endocrinol Invest. 1980. PMID: 6989887
References
MeSH terms
Substances
LinkOut - more resources
Medical